General Electric Co's GE Healthcare Announces Results From Tamoxifen And Exemestane Adjuvant Multinational Trial

General Electric Co's GE Healthcare announced results from the Tamoxifen and Exemestane Adjuvant Multinational (TEAM) Trial at the 2012 Annual Meeting of the American Society of Clinical Oncology. Results from this study, presented by John M.S. Bartlett, PhD of the Ontario Institute for Cancer Research demonstrated the ability of Mammostrat to predict distant relapse - free survival and disease- free survival for both exemestane and tamoxifen-exemestane treated estrogen receptor-positive (ER+) patients, irrespective of nodal status and chemotherapy. For this study, pathology blocks from 4598 patients were collected and tissue microarrays (TMAs) were constructed. All TMA cores were stained, and, utilizing Mammostrat, positivity for five biomarkers were assessed and assigned Mammostrat scores. In multivariate regression analyses, corrected for conventional clinicopathological markers, Mammostrat provided significant additional information on distant relapse-free survival (DRFS) after endocrine therapy in ER+ node negative patients (n=1226) patients not receiving chemotherapy (p=0.004). Further analyses in all patients not exposed to chemotherapy, irrespective of nodal status (n=2559) and in the entire cohort (n=3837) showed Mammostrat scores provide additional information on DRFS (p=0.001 and p<0.0001 respectively.